Davis J L, Bryan B, Simpkins H
Ann Clin Lab Sci. 1985 Jan-Feb;15(1):71-5.
A new cation-exchange microcolumn employing a borate buffer reportedly separates hemoglobin A1c from other labile glycosylated intermediates in a one step procedure. The effect of commonly occurring abnormal hemoglobins on the hemoglobin A1c (Hb A1c) levels as determined by this new technique has been studied and compared to the values obtained by isoelectric focusing. If a patient has hemoglobin levels in the normal range, or if HbS, HbE, or an elevated HbA2 are present, then hemoglobin A1c levels as estimated by this new column are unaffected or decreased. However, if HbF is elevated, a marked increase in the HbA1c level is observed. The increase is almost directly proportional to the HbF level up to 40 percent. This new column technique is therefore useful in eliminating labile glycosylated hemoglobin intermediates but must be coupled with other techniques if high HbF values are present.
据报道,一种采用硼酸盐缓冲液的新型阳离子交换微柱可在一步操作中从其他不稳定的糖化中间体中分离出血红蛋白A1c。研究了常见异常血红蛋白对通过这种新技术测定的血红蛋白A1c(Hb A1c)水平的影响,并与等电聚焦获得的值进行了比较。如果患者的血红蛋白水平在正常范围内,或者存在HbS、HbE或升高的HbA2,则通过这种新柱估计的血红蛋白A1c水平不受影响或降低。然而,如果HbF升高,则会观察到HbA1c水平显著增加。在高达40%的范围内,这种增加几乎与HbF水平成正比。因此,这种新的柱技术有助于消除不稳定的糖化血红蛋白中间体,但如果存在高HbF值,则必须与其他技术结合使用。